After Hours
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Most recently, Yahoo Finance reported about the stock as it publicized that Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $2.90 and fluctuated between $2.9475 as its day high and $2.8800 as its day low. The current market capitalization of Arbutus Biopharma Corp is $486.30M. A total of 1.47 million shares were traded on the day, compared to an average of 967.48K shares.
Insider Activity
Insider trades can also provide insight into a stock’s future direction. During the recent three months, ABUS has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, McElhaugh Michael J. sold 10,164 shares of ABUS for 2.31 per share on Feb 02. After the transaction, the Interim President & CEO now owns 1,504,793 company shares. In a previous transaction on Feb 02, Sofia Michael J. sold 9,982 shares at 2.31 per share. ABUS shares that Chief Scientific Officer owns now total 1,485,121.
Among the insiders who sold shares, HASTINGS DAVID C disposed of 9,593 shares on Feb 02 at a per-share price of $2.31. This resulted in the Chief Financial Officer holding 181,907 shares of ABUS after the transaction. In another insider transaction, Sims Karen sold 4,358 shares at $2.31 per share on Feb 02. Company shares held by the Chief Medical Officer now total 125,542.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for ABUS in the last 3 months, the mean price target is $4.60 with high estimates of $6.00 and low estimates of $4.00. In terms of 52-week highs and lows, ABUS has a high of $3.14 and a low of $1.69.
As of this writing, ABUS has an earnings estimate of $Arbutus Biopharma Corporation per share for the current quarter. EPS was calculated based on a consensus of Alpha Blue Capital US Small-Mid estimates, with a high estimate of $Acumen Pharmaceuticals, Inc. per share and a lower estimate of $Altice USA, Inc.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. ABUS’s latest balance sheet shows that the firm has $155.32M in Cash & Short Term Investments as of fiscal 2021. There were $2.61M in debt and $11.22M in liabilities at the time. Its Book Value Per Share was $0.71, while its Total Shareholder’s Equity was $169.44M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABUS is Buy with a score of 5.00.
